Stocktoria
Novo Nordisk A/S NOVO-B.CO
DK · Nasdaq Copenhagen · XCSE · stock · Healthcare · website
Novo Nordisk A/S statistics & valuation
Market capkr 1.39T
P / E13.6×
P / S4.5×
P / B7.2×
P / FCF48.0×
Dividend yield3.72%
Net margin33.1%
Return on equity52.8%
FCF margin9.4%
Multiples are price-derived and refreshed daily; everything else is from filings.
P / E vs its own history
Novo Nordisk A/S trades at about 13.7× earnings — below its 10-year norm (10-year range 16×–41.6×, median 38.6×).
13.7×
41.6×
Shaded band = 10-year range (16×–41.6×); dot = today's 13.7×.
Historical P/E = month-end price near each fiscal year-end ÷ that year's EPS. A read on whether the stock is cheap or dear relative to how it has typically been valued — not a forecast.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Gross margin | 81.0% | 84.7% | 84.6% | 83.9% |
| Operating margin | 41.3% | 44.2% | 44.2% | 42.3% |
| Net margin | 33.1% | 34.8% | 36.0% | 31.4% |
| FCF margin | 9.4% | 24.0% | 30.1% | 36.2% |
| Return on assets | 18.9% | 21.7% | 26.6% | 23.0% |
| Return on equity | 52.8% | 70.4% | 78.5% | 66.5% |
| Debt / equity | 0.58× | 0.59× | 0.15× | 0.25× |
| Current ratio | 0.80 | 0.74 | 0.82 | 0.89 |
Source: company filings via Yahoo Finance · DK · as of 2025-12-31. Figures in DKK; non-US fundamentals are aggregated by Yahoo (shorter history); facts plus Stocktoria's own computed scores — not investment advice.